[Macrolide-resistant Mycoplasma pneumoniae].

Area of Science:

• Pediatric infectious diseases
• Microbiology
• Antimicrobial resistance

Context:

• Mycoplasma pneumoniae is a primary cause of community-acquired pneumonia (CAP) in children.
• Macrolide-resistant M. pn emerged in Japan in 2000 and has since increased.
• ML resistance in M. pn is associated with a point mutation in domain V of the 23S rRNA gene.

Purpose:

• To investigate the clinical implications of macrolide-resistant Mycoplasma pneumoniae infections in pediatric CAP.
• To highlight the challenges in treating M. pn infections due to emerging antimicrobial resistance.

Summary:

• Macrolide-resistant M. pn strains, identified by a specific rRNA mutation, are increasingly prevalent in pediatric CAP cases.
• Patients with ML-resistant M. pn experienced significantly longer fever duration compared to those with susceptible strains.
• Treatment often required switching from macrolides to alternative antibiotics like minocycline or levofloxacin due to persistent symptoms.

Impact:

• The study underscores the growing threat of antimicrobial resistance in pediatric respiratory infections.
• Findings indicate a need for updated treatment guidelines and further research into effective chemotherapy for resistant M. pn infections.